Physician

Jennifer Lyn Cultrera, M.D.

According to 2025 Medicare claims, Jennifer Cultrera, M.D. (NPI: 1316041064) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32163-2040.

Cultrera's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,642 traditional Medicare patients, billed 328,278 HCPCS/CPT codes, and received $3,981,608 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,253 prescription claims across 542 beneficiaries totaling $4,341,742 in drug costs, led by Revlimid (Lenalidomide). DME data shows 15 claims. Open Payments data shows 156 records totaling $825,969. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,280,098 to $4,341,742. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,113 to $723.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,410	279,868	$3,122,874
2016	2,066	313,848	$4,026,523
2017	2,114	380,163	$5,254,099
2018	2,169	450,749	$5,739,024
2019	2,143	395,576	$5,391,129
2020	2,058	315,430	$4,145,038
2021	2,175	335,811	$4,734,054
2022	1,712	389,498	$4,383,606
2023	1,658	373,953	$4,321,177
2024	1,642	328,278	$3,981,608

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	322	1,583	$1,280,098
2016	330	2,115	$2,184,771
2017	388	2,245	$2,272,942
2018	452	2,592	$2,334,668
2019	469	2,716	$2,521,347
2020	465	2,262	$2,858,182
2021	477	2,371	$3,389,528
2022	526	2,616	$5,290,883
2023	596	2,733	$5,078,633
2024	542	2,253	$4,341,742

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	48	$30,235
2016	N/R	110	$27,819
2017	N/R	41	$3,584
2018	N/R	78	$7,760
2019	N/R	41	$3,886
2020	N/R	93	$5,735
2021	N/R	23	$280
2022	N/R	49	$2,640
2023	N/R	13	$2,522
2024	11	15	$2,708

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	841	2,179	$93
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	191	510	$46
96372	Injection of drug or substance under skin or into muscle	333	1,022	$10
36415	Insertion of needle into vein for collection of blood sample	1,070	3,017	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,033	3,196	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	82	2,177	$1,463,493
Imbruvica	Ibrutinib	34	952	$526,594
Jakafi	Ruxolitinib Phosphate	24	720	$419,563
Ibrance	Palbociclib	26	728	$397,866
Brukinsa	Zanubrutinib	19	570	$278,694

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	15	$2,708

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	77	$1,537	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	79	$824,431	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jennifer Lyn Cultrera, M.D.?

Tedicare shows public-source Medicare data for Jennifer Lyn Cultrera, M.D. (NPI 1316041064), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jennifer Lyn Cultrera, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jennifer Lyn Cultrera, M.D.?

Jennifer Lyn Cultrera, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Jennifer Lyn Cultrera, M.D. have Open Payments data?

Jennifer Lyn Cultrera, M.D. has 156 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.